SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

Naser Eddin Gharaibeh, Marie-Noel Rahhal, Leili Rahimi, Faramarz Ismail-BeigiDepartment of Medicine, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USAAbstract: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a major expan...

Full description

Bibliographic Details
Main Authors: Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F
Format: Article
Language:English
Published: Dove Medical Press 2019-07-01
Series:Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:
Fatty liver
insulin resistance
beta-oxidation
liver biopsy
de novo lipid synthesis
Online Access:https://www.dovepress.com/sglt-2-inhibitors-as-promising-therapeutics-for-non-alcoholic-fatty-li-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/sglt-2-inhibitors-as-promising-therapeutics-for-non-alcoholic-fatty-li-peer-reviewed-article-DMSO

Similar Items